A Review On The Development of Targeted Alpha Therapy in the Treatment of Cancer: EVERYDAY UROLOGY-Full Text Article

Everyday Urology-Oncology Insights: Volume 2, Issue 2

Focusing on The First and Only FDA Approved Targeted  Alpha Therapy Radium-223 in the Treatment of mCRPC

INTRODUCTION
The Tenth Symposium on Targeted Alpha Therapy (TAT-10) opened on Wednesday, May 31, 2017 in Kanazawa Japan. The symposium was jointly organized by the Joint Research Centre (JRC) of the European Commission and Kanazawa University as a forum for presentations on the latest developments in radiotherapy with alpha emitters in cancer. With over 200 participants the symposium covered advances in cancer treatment using alpha emitters as targeted therapy, clinical and preclinical research, radionuclide production, instrumentation and dosimetry.1

The Multidisciplinary Approach to Prostate Cancer Management: From Diagnosis and Beyond: EVERYDAY UROLOGY- Full Text Article

Everyday Urology-Oncology Insights: Volume 2, Issue 2

When patients receive a diagnosis of cancer it can be devastating. Suddenly their world is turned upside down, populated by doctors, diagnostic tests, and treatments.

Assessment of Cardiovascular Risk With the Use of Androgen Deprivation Therapy for Prostate Cancer: EVERYDAY UROLOGY- Full Text Article

Everyday Urology-Oncology Insights: Volume 2, Issue 1

Heart disease and cancer are the leading causes of death in the United States.1 Prostate cancer (PC) is the most common cancer in American men, and PC is most frequently diagnosed among men aged 65 to 74 years.2 The American Cancer Society’s estimates for PC in the United States for 2017 are about 161,360 new cases. Of these, about 26,730 are expected to die of the disease.1 

Enhanced Recovery After Surgery, Radical Cystectomy and Urinary Diversion: EVERYDAY UROLOGY-Full Text Article

Everyday Urology-Oncology Insights: Volume 2, Issue 1

Bladder cancer presents an ever increasing health care burden across the globe. The large majority of patients diagnosed with bladder cancer are over the age of 55, with an average age at the time of diagnosis of 73 and an increasing percentage 80 years and older.1 Men are about three to four times more likely to get bladder cancer during their lifetime than women.1

Radium-223:The Only Approved Targeted Alpha Therapy (TAT) in mCRPC- Outcomes, Opportunities and Lessons Learned : EVERYDAY UROLOGY- Full Text Article

Everyday Urology-Oncology Insights: Volume 2, Issue 1

More than 90% of patients with metastatic castration-resistant prostate cancer (mCRPC) develop bone metastases which leads to a significant increase in morbidity and mortality.1,2  Patients with metastatic prostate cancer and bone involvement have only a 3% five-year survival, whereas the five-year survival of patients without bone metastases is 56%. Skeletal-related events (SRE) in mCRPC patients may cause potentially devastating effects, such as decreased survival and pain, impaired mobility and spinal cord compression.2 Bone metastases and SREs diminish a patient’s quality of life and increase medical costs.3,4  

mCRPC Treatment: The Right Treatment for the Right Patient at the Right Time: EVERYDAY UROLOGY- Full Text Article

Everyday Urology-Oncology Insights: Volume 1, Issue 4

Metastatic castration-resistant prostate cancer (mCRPC) presents with a wide spectrum of symptoms with varying effects on patient quality of life. It is estimated that more than 90% of patients with metastatic castrate resistant prostate cancer (mCRPC) develop bone metastases that result in a significant increase in the risk of morbidity.1

First of its Kind: A Core Curriculum for Urologic Nursing: EVERYDAY UROLOGY-Full Text Article

Everyday Urology-Oncology Insights: Volume 1, Issue 4

The Core Curriculum is a first-of-its-kind textbook that can be used by nurses to study for specialty certification as a urology registered nurse, and is a source of material to support urology nursing instruction in academic programs. It has applicability to nurses in acute care, long term care, home care and rehab settings as all encounter patients with urologic problems.
Page 1 of 3